PPARGC1A and kidney disorder: This study is the first to elucidate the pathway by which Tan I exerts its effects, thereby enriching our understanding of PGC1α’s regulatory mechanisms in renal diseases and suggesting new therapeutic avenues for Tan I in renal fibrosis treatment.